Novo Nordisk A/S
Most Recent
Renaissance Technologies: Analyzing Its Q3 13F
At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.
Renaissance Technologies: Top Investments
Renaissance Technologies had a strong investment in the healthcare sector in Q2 2019. The healthcare sector makes up 18.16% of the firm’s total portfolio.
How NVO’s Revenues Are Trending in Fiscal 2019
Novo Nordisk (NVO) has guided for YoY revenue growth of 2% to 5% at a constant exchange rate in fiscal 2019.
What Analysts Recommend for GlaxoSmithKline and Novo Nordisk
GlaxoSmithKline (GSK) is up by 5.02%, and Novo Nordisk (NVO) is up by 10.51% in 2019 on a YTD basis.
GW Pharmaceuticals: Recommendations and Market Capitalization
Wall Street analysts estimate that GWPH stock could increase ~6.7% over the next 12 months.
Sanofi Stock Up 2.8% in September: What Lies Ahead?
On September 27, Sanofi’s (SNY) closing price was $44.84, and its market capitalization was $110.7 billion.
Sanofi Stock: How Much Upside Potential Does Wall Street See?
In the second quarter of fiscal 2018, Sanofi (SNY) reported sales of 8.2 billion euros, a YoY (year-over-year) decline in sales as well as profits.
Novartis to Divest Portions of Sandoz US to Aurobindo
Novartis (NVS) announced today that it has agreed to sell select portions of its Sandoz US portfolio to Aurobindo Pharma USA.
Novartis’s Sandoz in Q2 2018
Novartis’s (NVS) Sandoz reported nearly flat revenues at ~$2.46 billion in Q2 2018 compared to $2.45 billion in the second quarter of 2017.
Novo Nordisk’s Biopharmaceuticals Segment: An Update
Novo Nordisk’s (NVO) biopharmaceuticals segment generated revenues of 4.4 billion Danish kroner in the second quarter of 2018.
How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018
Novo Nordisk’s (NVO) premix insulin segment witnessed a ~1% YoY growth in local currencies in the first half of 2018.
Novo Nordisk’s Fast-Acting Insulins: A Performance Overview
In the first half of 2018, Novo Nordisk’s fast-acting insulins segment generated revenues of 9.7 billion Danish kroner, a ~2% YoY growth.
Novo Nordisk’s Long-Acting Insulins: A Performance Overview
Tresiba, Novo Nordisk’s (NVO) long-acting insulin, generated revenues of 3.7 billion Danish kroner in the first half of 2018.
Novo Nordisk: A Financial Overview after the First Half of 2018
Novo Nordisk (NVO) had net revenues of 54.3 billion Danish kroner in H1 2018 compared to 57.1 billion Danish kroner in H1 2017.
What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2
GlaxoSmithKline’s (GSK) Consumer Healthcare segment includes its wellness, oral health, nutrition, and skin health products.
Analysts’ Recommendations for Sanofi Stock before Q2 Results
Sanofi (SNY) is scheduled to announce its earnings results for the second quarter of fiscal 2018 on July 31.
Novartis’s Q2 2018 Earnings: Sandoz
Sandoz, the generics arm of Novartis (NVS), reported nearly flat revenues at ~$2.46 billion during Q2 2018.
Novartis Reports Growth in Q2 2018 Earnings
Novartis (NVS) released its Q2 2018 earnings on July 18 and surpassed Wall Street analysts’ estimates for revenues and EPS.
NVO’s Victoza and Ozempic Could See Steady Growth in 2018
In June, Novo Nordisk presented the post hoc analysis of the SUSTAIN 7 trial.
The Performance of Novo Nordisk’s Premix and Fast-Acting Insulin
Novo Nordisk’s human insulin generated revenues of 2.37 billion Danish kroner in Q1 2018, compared with 2.5 billion Danish kroner in Q1 2017, reflecting an ~6.0% YoY decline.
Oral Semaglutide Could Be Novo Nordisk’s Long-Term Growth Driver
In June, Novo Nordisk (NVO) presented the results of its Phase 3a PIONEER 1 trial.
A Look at Novo Nordisk’s Financial Position
Novo Nordisk (NVO) reported Q1 2018 revenues of 26.9 billion Danish kroner, compared to 28.5 billion Danish kroner in Q1 2017—down ~5% YoY.
Sanofi Announces Positive Study Results for Toujeo
On June 25, Sanofi (SNY) announced positive results for BRIGHT, a study comparing Sanofi’s Toujeo with Novo Nordisk’s (NVO) Tresiba (degludec).
How Sanofi’s Valuation Compares
Sanofi (SNY) has recently been working on expanding its product portfolio in areas with potential growth and strong margins.
Analysts See a 9.5% Upside for SNY Stock over the Next Year
Of the five analysts covering SNY stock on June 27, two recommended “strong buy,” and three recommended “hold.”
How the Healthcare Sector’s Dividend Yield Stacks Up
The healthcare industry has an average dividend yield of 1.9%.
Analysts’ Recommendations for GlaxoSmithKline in May
GSK reported EPS of 24.60 British pence on revenue of 7.22 billion pounds, surpassing Wall Street analysts’ consensus estimates.
AstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
AstraZeneca (AZN) is one of the leading pharmaceutical companies that deals with primary care and specialty care products.
GlaxoSmithKline’s Pharmaceutical Business in 1Q18
GlaxoSmithKline’s (GSK) Pharmaceuticals business includes various Immuno-inflammation products, HIV products, Respiratory products, and Established products.
NVS and NVO: Which Has Higher Upside Potential?
Novartis’s (NVS) EV (enterprise value) is $206.9 billion and its EV-to-revenue ratio is 4.1.
Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018
In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY growth.
Novo Nordisk’s Victoza Could See High Growth in 2018
In 4Q17, Novo Nordisk’s (NVO) Victoza generated revenues of 6.3 billion Danish kroner.
A Review of Novo Nordisk’s Modern Insulin
In 4Q17, Novo Nordisk’s (NVO) modern insulins generated revenues of 10.4 billion Danish kroner.
Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.
Novo Nordisk’s Xultophy Expected to See High Growth in 2018
In fiscal 2017, Novo Nordisk’s (NVO) Xultophy had revenues of 729 million Danish kroner compared to 207 million Danish kroner in 2016.
Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY growth in local currencies.
Analysts’ Recommendations for Novartis on April 17
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16.
Novo Nordisk Stock Performance in 1Q18
Wall Street analysts estimate that Novo Nordisk (NVO) stock will increase 21.7% over the next 12 months.
Novartis’s Innovative Medicines Business in 4Q17
Overall, the innovative medicines business accounted for ~67.8% of Novartis’s total revenues.
How AstraZeneca’s Other Products Portfolio Performed in 4Q17
AstraZeneca’s (AZN) other products portfolio reported revenues of ~$1.1 billion during 4Q17, a 17% decline in operating revenues.
How AstraZeneca’s Revenues Trended in 4Q17
AstraZeneca (AZN) reported 2% growth in operating revenues to ~$5.8 billion during 4Q17 as compared to the revenues of ~$5.6 billion during 4Q16.
Semaglutide May Prove to Be an Effective Anti-Obesity Therapy
Novo Nordisk plans to initiate its Phase 3a program, STEP, to study the efficacy of 2.4 mg of semaglutide once per week in obesity indications in 1H18.
Saxenda May Continue to Lead in the Diabetes Segment in 2018
In 2017, Novo Nordisk’s (NVO) Saxenda sales reached 2.6 billion Danish kroner, a YoY (year-over-year) rise of 64%.
Label Expansion May Boost Xultophy’s Sales in 2018
In November 2017, Novo Nordisk (NVO) submitted an application to European regulatory authorities to update Xultophy’s label.
Xultophy May Prove a Strong Growth Driver for NVO in 2018
Novo Nordisk’s (NVO) Xultophy reported sales close to 729 million Danish kroner in 2017.
Novo Nordisk Has Developed a Portfolio of New-Generation Insulins
Novo Nordisk has been creating awareness about the risks of hypoglycemia and the benefits of Tresiba among general practitioners and primary care physicians.
Novo Nordisk Focuses on Creating Buzz about Tresiba’s Benefits
Novo Nordisk (NVO) is anticipating the FDA’s decision related to the inclusion of hypoglycemia data from its DEVOTE and SWITCH studies by the end of 1Q18.
Tresiba Emerged as a Blockbuster Therapy in 2017
In 2017, Novo Nordisk’s (NVO) basal insulin therapy, Tresiba, reported revenue of nearly 7.3 billion Danish kroner and attained blockbuster status.
Will NVO Continue to Lead the Global Insulin Market in 2018?
Novo Nordisk (NVO) has adopted a market-fit strategy, offering insulin products that are suitable for the different demands of patients in different geographies.
Novo Nordisk Has a Broad Portfolio for Type 2 Diabetes Care
According to IQVIA, the global insulin market value grew at a compound average growth rate (or CAGR) of 16.8% from November 2012 to November 2017.
Diabetes Care Segment Continues to Drive Growth for NVO in 2018
According to the International Diabetes Federation, ~10% of adults in the world are affected by diabetes.
Oral Semaglutide May Drive Solid Growth for NVO Going Forward
On February 22, 2018, Novo Nordisk (NVO) announced the results of its 26-week Phase 3a trial, PIONEER 1.
Alexion Pharmaceuticals: Strensiq and Kanuma in 2017
In 4Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenues of $95.6 million, which reflected ~35% growth on a YoY (year-over-year) basis.
Victoza Continues to Lead in the GLP-1 Segment in 2018
In 3Q17, Novo Nordisk managed to update Victoza’s label in the United States and Europe.
GLP-1 Drug Class May Continue to Drive Growth for Novo Nordisk
According to IQVIA, glucagon-like peptide products currently account for only a 12% share of the global diabetes care market by value.
Analyst Ratings and Recommendations for Sanofi
In 4Q17, Sanofi reported earnings per share of 1.06 euros on revenues of 8.7 billion euros.
Sanofi’s Established Prescription Products in 4Q17
Renagel and Renvela reported revenues of 155.0 million euros in 4Q17, a 28.5% decline in operating revenues compared to 4Q16.
Performance of Sanofi’s Business Segments in 4Q17
Sanofi Pasteur reported revenues of ~1.4 billion euros in 4Q17 for 8.7% growth in operating revenues compared to its 4Q16 revenues.
Novo Nordisk Expected to Report Flat Revenue in 2018
Flat revenue performance In its 4Q17 earnings conference call, Novo Nordisk (NVO) has projected sales to be 2%–5% higher YoY (year-over-year) in 2018 in local currency. However, the company also anticipates a seven-percentage-point impact due to unfavorable currency fluctuations, which could impact its revenue growth rate. The company accounts for 27% of the global diabetes care market and […]
Analysts’ Recommendations for Novo Nordisk and Peers in 2018
Novo Nordisk (NVO) reported sales of ~112 billion Danish kroner in fiscal 2017.
A Look at Ablynx and Sanofi’s Existing Partnership
On January 29, 2018, Sanofi (SNY) announced that it had agreed to acquire Ablynx (ABLX) for 3.9 billion euros.
Highlights of Sanofi’s 3.9 Billion Euro Ablynx Acquisition
On January 29, 2018, Sanofi announced its acquisition of Belgium-based Ablynx for 45 euros per share, amounting to a total of 3.9 billion euros (or $4.8 billion) in cash.
Analysts’ Updates after Sanofi’s Bioverativ Announcement
In this article, we’ll have a look at Wall Street’s recommendations and target prices following Sanofi’s Bioverativ acquisition announcement.
Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.
Analysts’ Recommendations for Novartis after Its 4Q17 Earnings
Novartis (NVS) is expected to report earnings per share of $1.26 in 1Q18 compared to EPS of $1.13 in 1Q17.
Novartis’s 4Q17 Earnings: Sandoz Business
Sandoz reported a decline of 4.0% in operating revenues, offset by a 4.0% positive impact of foreign exchange.
Novartis’s 4Q17 Earnings: Segment-Wise Revenues
Novartis (NVS) reported revenues of ~$12.9 billion in 4Q17, representing 5.0% growth in revenues compared to ~$12.3 billion in 4Q16.
How Sanofi Can Benefit from Ablynx Acquisition
On January 29, 2018, Sanofi entered an agreement with Ablynx where Sanofi will acquire all of the outstanding ordinary shares of Ablynx.
Reading the Estimates for Novartis’s Alcon in 4Q17
For 4Q17, Alcon is expected to report growth in revenues, driven by the increased demand for contact lenses and surgical products.
What’s Expected of Novartis’s Sandoz Segment in 4Q17?
Sandoz’s positive revenue growth in 4Q17 is expected to be driven by strong sales in European markets and the rest of the world (excluding the US).
Behind Novartis’s 4Q17 Estimates: Innovative Medicines
The Innovative Medicines segment is expected to report growth in operating revenues for 4Q17.
Behind Novartis’s 4Q17 Earnings: Why Some Expect Revenue Growth
Analysts expect Novartis’s revenues to rise ~3.9% to $12.8 billion in 4Q17, driven by growth in operating revenues across all three segments.
How Is Bioverativ’s Eloctate Positioned Now?
In 3Q17, Bioverativ’s (BIVV) Eloctate generated revenue of $186.3 million, reflecting a 41% rise on a year-over-year (or YoY) basis.
How Is Roche’s Hemlibra Positioned for 2018?
Roche’s (RHHBY) Hemlibra is used for the prevention and reduction of the frequency of bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.
How Is Novo Nordisk’s New Generation Insulin Segment Positioned after 3Q17?
In 3Q17, Novo Nordisk’s (NVO) new generation insulin generated revenues of 2.1 billion Danish krone (or DKK), which reflected ~93% growth on a year-over-year (or YoY) basis.
How Did Novo Nordisk’s Modern Insulin Segment Perform in 3Q17?
In 3Q17, Novo Nordisk’s (NVO) NovoRapid reported revenues of 5.0 billion Danish krone (or DKK), which reflected ~9% growth on year-over-year (or YoY) basis.
Novo Nordisk’s Xultophy, Ryzodeg, and Fiasp Could Boost Revenue Growth in 2018
Novo Nordisk’s (NVO) Xultophy (insulin degludec and liraglutide combination) is used as an addition to diet and exercise for improvement of blood sugar levels in adults with type-2 diabetes mellitus whose blood sugar level could not be controlled adequately with basal insulin.
How Did Novo Nordisk’s NovoMix and Human Insulin Perform in 2017?
In 3Q17, Novo Nordisk’s (NVO) NovoMix reported revenues of 2.4 billion Danish krone (or DKK), which reflected ~1% growth on year-over-year (or YoY) basis.
How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
Ozempic Could Boost Novo Nordisk’s Revenue Growth in 2018
In December 2017, the U.S. FDA (Food and Drug Administration) approved Novo Nordisk’s (NVO) Ozempic as an addition to diet and exercise for the improvement of blood sugar levels in individuals with type two diabetes mellitus.
How Did Novo Nordisk’s Victoza and Saxendra Perform in 3Q17?
In 3Q17, Novo Nordisk’s (NVO) Victoza reported revenues of 5.3 billion Danish krone (or DKK), which reflected ~9% growth on a year-over-year (or YoY) basis.
How Did Invokana Perform in 3Q17?
Invokanna reported year-to-date (or YTD) September 2017 revenues of $844 million compared to $1.0 billion in YTD (year-to-date) September 2016.
Behind Sanofi’s Generics and Consumer Healthcare Business in 3Q17
Sanofi’s (SNY) general medicines and emerging markets sub-segment reported revenues of 433 million euros in 3Q17, representing a 0.9% YoY fall.
Behind Sanofi’s Genzyme Business in 3Q17
Sanofi’s genzyme business reported revenues of 1.63 billion euros in 3Q17, representing a 12.5% YoY (year-over-year) rise in operating revenues.
How Eli Lilly’s Trajenta, Trulicity, and Basaglar Are Performing
In 3Q17, Eli Lilly’s (LLY) Trajenta generated revenues of $153.3 million, ~33% growth on a year-over-year (or YoY) basis and ~8% growth on a quarter-over-quarter basis.
How Eli Lilly’s Forteo and Jardiance Are Performing
In 3Q17, Eli Lilly’s (LLY) Forteo generated revenues of $441.7 million, ~13% growth on a year-over-year (or YoY) basis and a 1% decline on a quarter-over-quarter basis.
How Eli Lilly’s Endocrinology Drugs Are Performing
In 3Q17, Eli Lilly’s (LLY) Humalog generated revenues of $696.2 million, ~9% growth on year-over-year (or YoY) basis and 3% growth on a quarter-over-quarter basis.
Analysts’ Recommendations for GlaxoSmithKline in November 2017
Wall Street analysts estimate that GlaxoSmithKline’s (GSK) top line could fall 0.8% to ~7.5 billion pounds in 4Q17.
AstraZeneca’s Performance by Segment in 3Q17
The CVMD segment reported a 4% fall in revenues at constant exchange rates to ~$1.8 billion during 3Q17.
Behind Sanofi’s 3Q17 Revenue Growth
Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.
Why Sanofi’s Revenues Could Fall in 3Q17
Analysts estimate Sanofi’s (SNY) revenues will fall 2.2% to 9.44 billion euros during 3Q17.
Alnylam Saw Serious Adverse Event in Fitusiran Phase 2 OLE Study
On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had suspended all of its fitusiran studies after a serious adverse event (or SAE).
Novo Nordisk Stock: Performance in 3Q17
Novo Nordisk stock has risen ~12.3% in 3Q17. It has risen ~41.3% year-to-date as of October 20, 2017.
Sanofi Stock: Performance in 3Q17
Sanofi stock has risen ~3.9% in 3Q17. It has risen 22.5% year-to-date as of October 20, 2017.
What GlaxoSmithKline’s 3Q17 Performance Tells Us
GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.
Behind Merck’s Performance in 3Q17
MRK stock rose ~0.6% in 3Q17 and has risen ~7.7% YTD (year-to-date) as of October 16.
Why Eli Lilly’s Basaglar, Jardiance, and Trajenta Could Witness Steady Growth in 2018
In 1H17, Eli Lilly’s (LLY) Basaglar generated revenues of around $132.6 million, compared with $27.2 million in 1H16.
A Look at Novo Nordisk’s Hemophilia Franchise after 2Q17
In the first half of 2017, Novo Nordisk’s hemophilia franchise reported revenues of DKK 5.3 billion, which reflected a ~1.0% fall on a YoY (year-over-year) basis.
How Is Novo Nordisk’s Victoza Positioned after 2Q17?
In the first half of 2017, Novo Nordisk’s (NVO) Victoza generated revenues of DKK (Danish kroner) 11.5 billion, which reflected a ~21.0% rise on a YoY (year-over-year) basis.
Xultophy Could Substantially Boost Novo Nordisk’s Revenue Growth
In the first half of 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of DKK (Danish kroner) 284.0 million.